|
|
|
|
|
|
By Business Of Bio Podcast | Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire. |
|
|
|
|
|
| Current And Emerging Technologies To Optimize mRNA Manufacturing | Article | By Clemens Jakobi, Michał Domański, and Telmo Graça, Lonza | Explore the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production. |
|
|
| Navigate The Evolving Antibody Therapeutic Landscape | Article | Pfizer CentreOne | There are several important factors that developers and manufacturers will need to consider to effectively support antibody therapeutics and navigate the trends and challenges on the horizon. |
|
|
|
|
|
|
|
|
|
| A ballooning clinical-stage ADC development community is putting stress on both manufacturing capacity and antibody engineering and conjugation talent. What does this burgeon mean for ADC manufacturing, process development, and, ultimately, clinical progress? Join Bioprocess Online Live on July 9th as we navigate the complexity of the ADC manufacturing environment. From linkers to payloads to conjugation, we’ll cover the lay of the land for developers. Registration is free thanks to the support of Cytiva. |
|
|
|
|
|
|
|
|
|
|
|
|
Connect With Bioprocess Online: |
|
|
|